48 results about "Antigen epitope" patented technology

The application provides a cell fixing solution for a myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) and a product and application thereof, and relates to the technical field of in-vitro detection. The cell fixing solution provided by the application is composed of polyoxymethylene, formaldehyde, acetic acid, raffinose and a buffer solution, can effectively fix the cell morphology, maximally retains the natural spatial conformation and antigen epitope integrity of myasthenia gravis related antigens AChR, Titin, RyR1, MuSK and LRP4, reduces the problems of antigen denaturation, epitope shielding and protein loss in the fixing process, can efficiently and accurately realize the synchronous joint detection of various specific antibodies, and the myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) prepared by the application has stable detection results, and has important clinical application value and industrial popularization prospect.

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

This invention relates to the field of biotechnology, and in particular to an antigenic epitope peptide, product, and application for detecting antibodies produced by porcine deltacoronavirus infection. This invention identified short peptide epitopes in PDCoV longitudinal challenge serum samples, obtaining 12 short peptides, which were then prepared into a porcine deltacoronavirus antibody detection kit. Finally, six field serum samples were selected for antibody detection, and the effectiveness was verified using a virus neutralization experiment. The results showed that the porcine deltacoronavirus antibody detection kit provided by this invention is effective. Furthermore, the porcine deltacoronavirus antibody detection kit provided by this invention, as a novel detection method, improves sensitivity and specificity while simultaneously providing multiple detection results, namely, determining whether viral infection has occurred, identifying the stage of infection, and achieving DIVA (Differentiation, Infection, and Variability) analysis.

The application discloses a porcine rotavirus VP7 protein conserved dominant B cell antigen epitope peptide or a combination thereof or a nucleic acid molecule and application, and further discloses a porcine rotavirus VP7 protein polyepitope fusion protein and a preparation method and application thereof.The polyepitope fusion protein can not only induce high-level specific antibody response and cellular immune response to the VP7 protein, effectively inhibit porcine rotavirus infection, but also has high safety and stability.Compared with a traditional fusion protein, the polyepitope fusion protein has significant advantages in production cost and immunization efficacy, and provides a feasible porcine rotavirus prevention and control scheme for the pig industry.

The application belongs to the field of marine biotechnology, and specifically discloses a preparation method of a long oyster insulin-like peptide receptor (ILPR) polyclonal antibody and application thereof. The method is characterized by the following steps: specific antigen epitopes of the long oyster ILPR protein are screened through bioinformatics analysis, a pET32a-ILPR recombinant plasmid is constructed and induced to express in Escherichia coli; the purified recombinant protein is used as an immunogen to immunize New Zealand white rabbits, and rabbit antisera are collected after four times of booster immunization; specific polyclonal antibodies are purified by using antigen affinity chromatography technology, and can specifically recognize the ILPR protein in long oyster tissues. The antibody prepared by the application has high specificity and sensitivity, and provides an important biological tool for studying the insulin signal transduction pathway, growth regulation and energy metabolism mechanism of long oysters.

This invention belongs to the field of biomedical technology, specifically relating to an antigenic epitope peptide combination for a broad-spectrum novel coronavirus vaccine and its application. The antigenic epitope peptide combination of this invention includes a combination of viral spike protein Epi-I antigenic epitope peptides, a combination of viral spike protein Epi-II antigenic epitope peptides, and a combination of viral spike protein Epi-III antigenic epitope peptides. These antigenic epitope peptide combinations are obtained by screening spike protein epitopes from three broad-spectrum neutralizing antibodies against SARS-CoV-2, and can induce a broad-spectrum neutralizing antibody response in the host, used for the preparation of a broad-spectrum novel coronavirus vaccine. Using the antigenic epitope peptide combination of this invention, an antigenic epitope fusion protein L9 was obtained and prepared into a vaccine. The results of the examples show that the L9 vaccine has a better neutralizing effect against SARS-CoV-2 variants than the control group of the Wuhan strain of SARS-CoV-2 spike protein RBD, exhibiting good cross-neutralization.

The application discloses a targeting superantigen fusion protein based on an improved SE(3)-Transformer and an implementation method. In an offline stage, amino acid sequences are first converted into one-hot encoding or language model embedding (such as ESM-2), and are spliced with multiple sequence alignment (MSA) features for geometric initialization. A neural network (improved SE(3)-Transformer) combined with multiple sequence alignment (MSA) and an attention mechanism is constructed to predict the coordinates of C alpha, C, N and O atoms for main chain prediction, and the neural network is trained through a gradient descent method based on a physical heuristic potential item. In a verification stage, the improved SE(3)-Transformer after training is used to generate a predicted structure, conformational stability is verified through a simplified force field, and fine tuning is performed based on a confidence score. The application can accurately predict the structure of a target antigen epitope and an antibody variable region, optimize a superantigen functional domain in combination with a graph neural network, and dynamically design a flexible connecting peptide to realize modular fusion.

The application belongs to the technical field of immunotherapy, and particularly relates to an antigen epitope peptide of a tumor cell high-expression antigen LY6K and application thereof. The technical problem to be solved by the application is to provide a new method for treating or clinically detecting a tumor high in LY6K expression. The technical scheme of the application is an antigen epitope peptide of a tumor cell high-expression antigen LY6K, the amino acid sequence of which is shown in SEQ ID No. 4. The application provides a LY6K antigen epitope peptide, and a pMHC complex or an antigen presenting cell directly loaded with the antigen epitope peptide can activate T cells. Therefore, the antigen epitope peptide can be applied to treatment or diagnosis of a tumor high in LY6K antigen expression.

The application discloses an ELISA antibody detection kit for identifying Brucella gene deletion live vaccine (M5-90△26 strain) and wild strains and application. The kit comprises enzyme-linked reaction plate 1 and enzyme-linked reaction plate 2. The enzyme-linked reaction plate 1 is coated with LPS extracted from the Brucella gene deletion live vaccine (M5-90△26 strain), and the enzyme-linked reaction plate 2 is coated with a Brucella BP26 antigen epitope polypeptide combination composed of polypeptides with amino acid sequences shown in SEQ ID NO:1-2. The application is suitable for goats and sheep inoculated with the Brucella gene deletion live vaccine (M5-90△26 strain), can effectively distinguish the antibody produced by the Brucella gene deletion live vaccine (M5-90△26 strain) and the antibody produced by wild strain infection, thereby realizing identification and detection, being favorable for prevention and control of brucellosis and optimization of a vaccination strategy, and providing technical support for healthy and sustainable development of animal husbandry.

This invention belongs to the field of vaccine technology, specifically relating to a method for effectively activating the body's immune system against tuberculosis infection by identifying candidate antigen epitopes for mRNA vaccines. The method comprises the following steps: screening for population-specific tuberculosis protective antigens based on reverse prediction from a TCR immune repertoire; constructing an mRNA vaccine containing these population-specific tuberculosis protective antigens and identifying the optimal antigen; and evaluating the in vivo immunogenicity, immunogenicity, and immunoprotective effects of the mRNA vaccine. This technical solution combines population-specific common HLA allele profiles with existing tuberculosis-specific TCR databases to target and predict broad-spectrum protective antigens recognized by TCRs shared under the major HLA backgrounds in the population. LNP-mRNA vaccine technology has been established as an ideal platform for delivering these newly discovered advantageous antigens.

The present application belongs to the technical field of bioengineering. The present application relates to a recombinant protein, which comprises two dominant antigen epitopes of feline calicivirus (FCV) protein. In order to improve the yield of the recombinant protein in a prokaryotic expression system, the amino acid sequence of the recombinant protein is converted into a corresponding nucleotide sequence by using E. coli preferred codons, the nucleotide sequence is chemically synthesized, and a recombinant expression vector is constructed. The present application also relates to the establishment of a phage library by immunizing mice with the recombinant protein, the screening of a single-chain antibody (scfv) sequence corresponding to the feline calicivirus recombinant protein by panning, the construction of a complete mouse IgG1 antibody sequence expression vector from the obtained scfv sequence, the expression of a monoclonal antibody by instantaneously transferring HEK293F cells, the purification of the monoclonal antibody, and the labeling of europium ions (Eu 3+ ) in the monoclonal antibody, respectively. The optimal monoclonal antibody pairing combination is determined by orthogonal experiments, and the monoclonal antibody can be used for the early diagnosis of upper respiratory tract infection in cats.

The application belongs to the technical field of bioactive peptides and antibodies, and discloses an antigen epitope peptide of CaSR, a vaccine, an antibody and application. The application aims to use polypeptide vaccine technology to construct yolk antibody targeting CaSR in the intestinal tract, improve calcium absorption efficiency of poultry, seek a scheme for efficient utilization of calcium elements of poultry, and realize calcium saving and emission reduction in production.

The application relates to preparation, epitope identification and application of a PRV TK protein monoclonal antibody, the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO. 2, and the amino acid sequence of the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 3. Meanwhile, the application provides a PRV TK protein antigen epitope peptide, and the specific amino acid sequence of the PRV TK protein antigen epitope peptide is shown as SEQ ID NO. 4. On the basis of successfully expressing a PRV strain TK protein, the PRV strain TK protein is purified and used as an antigen to immunize mice, and a hybridoma technology is used to prepare a specific monoclonal antibody for the PRV strain TK protein, so as to provide an important tool for TK protein structure and function research of a PRV epidemic strain, and subsequent establishment of a PRV specific diagnosis method and related research.

The application discloses an antibody for detecting cardiovascular diseases and application thereof, and belongs to the technical field of biological medicine. The monoclonal antibody or antigen binding fragment thereof provided by the application can specifically bind to a specific antigen epitope (SEQ ID NO:1) of human cardiac troponin I (cTnI) and has no cross reaction with skeletal muscle troponin I. The application further discloses the CDR sequences of the heavy chain and light chain variable regions of the antibody, a coding gene, a preparation method and application thereof. An ELISA detection kit containing the antibody can specifically recognize cTnI in a blood sample, has good linearity in the range of 0.01-50 ng / mL, has a false negative rate of 0 for serum detection of patients with acute myocardial infarction, and has a low false positive rate for serum detection of healthy people. The antibody and the kit have important application value in rapid and accurate diagnosis of cardiovascular diseases such as acute myocardial infarction.

The application discloses an ELISA kit for detecting anti-human laminin gamma 1 IgA autoantibody and application thereof. The kit comprises an enzyme-labeled plate coated with human laminin gamma 1 recombinant protein. Preferably, the human laminin gamma 1 recombinant protein is deglycosylated human laminin gamma 1 recombinant protein. Further, the application also provides application of the kit in preparation of a reagent for diagnosing mucous membrane pemphigoid, in particular Laminin gamma 1 IgA type pemphigoid. The kit is the first kit for detecting human laminin gamma 1 IgA antibody by using the ELISA method, has the advantages of simple operation, short time consumption and low cost compared with traditional immunoblotting method, and adopts full-length deglycosylated laminin gamma 1 recombinant protein as an antigen, thereby solving the problem of incomplete antigen epitope coverage in the prior art, and early detection of diseases can be realized, early treatment is achieved, and the life quality of patients is improved.

The application discloses an epitope tandem polypeptide of porcine reproductive and respiratory syndrome and related biological materials and application thereof, and belongs to the field of viral antigen vaccines or biomedical technologies. The application provides an epitope tandem polypeptide which is composed of neutralizing antigen epitopes, Th epitopes and CTL epitopes of multiple structural proteins and non-structural proteins of PRRSV in series, and includes PNB, PTH and PCTL. The epitope tandem polypeptide provided by the application can be directly used for preparing a subunit vaccine of PRRSV, and has the advantages of simple preparation method, strong immunogenicity and good safety. The epitope tandem polypeptide can also be combined with an inactivated vaccine of PRRSV and applied to enhance cellular immunity induced by the inactivated vaccine, so that the epitope tandem polypeptide can more effectively prevent and protect pigs from PRRSV infection. The epitope tandem polypeptide composition contains common epitope sequences of seven representative strains (LV, VR-2332, CH-1a, JXA1, NADC30, NADC34 and RFLP 1-4-4) of PRRSV, and is expected to have good cross-protection for infection of different strains.

The application provides an antigen epitope peptide and a paralichthys olivaceus mucin Muc13 specific antibody prepared by the antigen epitope peptide, determines a B cell epitope from the paralichthys olivaceus Muc13 protein through antigen epitope screening, and the sequence is PGTTEEPDPTAGSPP. After the epitope is coupled with a KLH carrier protein, the epitope is used for immunizing New Zealand white rabbits, and a rabbit-derived anti-paralichthys olivaceus Muc13 specific antibody is successfully obtained. The antibody can specifically recognize the Muc13 protein in paralichthys olivaceus mucosa tissue and Muc13 positive mucous cells, and provides a key detection means for in-depth exploration of the function mechanism of mucous cells in the fish mucosa immune response process.

This invention discloses a novel coronavirus T-cell antigenic epitope peptide and its application in vaccine preparation. The amino acid sequence of the novel coronavirus T-cell antigenic epitope peptide is shown in any one of SEQ ID NO: 1 to 9. A pMHC complex monomer was prepared using this peptide, and a pMHC complex polymer was further prepared. These can be used to detect antigen-specific T cells in the peripheral blood of novel coronavirus vaccine recipients and recovered patients, and for in vitro T-cell activation experiments. These novel coronavirus T-cell antigenic epitope peptides can be used in the preparation of universal vaccines against various novel coronavirus mutant strains, novel coronavirus-related immune detection, and the development of broad-spectrum therapeutic drugs, and are worthy of in-depth research and widespread promotion.

This invention relates to the field of power system automation and fault prediction technology, and discloses a data analysis-based method and system for distribution network fault identification. The method includes: constructing a digital twin model of the distribution network to generate a self-sample set of normal operating conditions; training a set of mature detectors using an adaptive immune learning algorithm based on the self-sample set to define non-self regions; real-time acquisition and preprocessing of field operating data, inputting it into the detector set for anomaly identification; mapping the identified non-self signals back to the digital twin model, and determining the physical causes and development paths of faults through antigen epitope correlation analysis and evolutionary deduction. The system includes a digital twin simulation module, an immune learning processing module, a real-time acquisition and preprocessing module, a state matching monitoring module, and a fault deduction and correlation analysis module.

The application discloses a monoclonal antibody and application. A monoclonal antibody is secreted by a hybridoma cell strain 6B12G10, and an antigen epitope recognized by the monoclonal antibody is aa130-aa134 of a P30 protein of a gene I type African swine fever virus. An amino acid aa131 of the P30 protein is E. The application prepares a monoclonal antibody capable of identifying the P30 antigen of the gene I type African swine fever virus; the monoclonal antibody can directly distinguish the gene I type and the gene II type, the gene I / II recombinant type ASFV by using an indirect immunofluorescence technology; for type identification after infection of an ASFV weak strain, the application establishes a blocking ELISA method, and for the first time, effectively distinguishes whether the gene I type ASFV is infected or the gene II type, the gene I / II recombinant type ASFV is infected, effectively fills a differential diagnosis blank in the domestic and foreign aspects, and has important significance for tracing a gene I type ASFV infection.

The application provides an antigen epitope polypeptide and a paralichthys ovatus mucin Muc5b specific antibody prepared by the antigen epitope polypeptide, a B cell antigen epitope of the paralichthys ovatus Muc5b protein is screened, the amino acid sequence of the B cell antigen epitope is shown as NDKQRSKQCEDYQVV, a New Zealand white rabbit is immunized after the antigen epitope is coupled with a KLH carrier protein, and a rabbit anti-paralichthys ovatus Muc5b specific antibody is prepared. The antibody can specifically recognize the Muc5b protein in paralichthys ovatus mucosa tissue and positive mucous cells, and provides a key detection tool for in-depth exploration of the function mechanism of mucous cells in the paralichthys ovatus mucosa immune response process.

This invention relates to the field of biotechnology and provides an antigenic epitope of the parainfluenza virus type 5 F protein, a monoclonal antibody, and its applications. 135 AAILNLKNAIQKTNAAVADVVQA 157 Furthermore, a monoclonal antibody that specifically recognizes this antigenic epitope is provided. The amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2. The discovery of this epitope provides a new target for the development of PIV5 diagnostic reagents. Peptide antigens can be designed and synthesized based on this epitope to develop highly specific ELISA diagnostic kits. Simultaneously, this epitope can be used as a candidate epitope for the design of multi-epitope vaccines, providing a new strategy for the prevention and control of PIV5.

The application relates to the technical field of immunomagnetic bead preparation, in particular to a composite antibody immunomagnetic bead with a ring-shaped magnetic attraction structure and a preparation method and application thereof. After being cleaned and activated, the magnetic bead is coupled with at least two kinds of composite anti-red blood cell antibodies with different antigen epitopes, and after being sealed, free anti-red blood cell antibodies are added to prepare a vacuum freeze-dried product; through a matched ring-shaped magnetic attraction structure, a plurality of trapezoidal permanent magnets are assembled according to a Halbach array, the periphery is fixed through a ring-shaped stainless steel sleeve, and a uniform radiation ring-shaped magnetic field is formed; when applied, a mixed solution of whole blood and the magnetic bead is placed in the center hole of the structure and is magnetically attracted for 10-90 seconds; the composite antibody immunomagnetic bead with the ring-shaped magnetic attraction structure and the preparation method and application thereof can significantly improve the red blood cell capturing and separation efficiency, shorten the separation time, reduce the magnetic bead consumption, facilitate plasma suction, cover most clinical scenes, and reduce the industrialization cost.

The application provides an antigen epitope polypeptide and a paralichthys ovatus mucin Muc1 specific antibody prepared by the antigen epitope, a B cell epitope from the paralichthys ovatus Muc1 protein is identified through antigen epitope screening, and the amino acid sequence is SEQ ID NO:1. After the epitope is coupled with a KLH carrier protein, a New Zealand white rabbit is immunized, and a rabbit anti-paralichthys ovatus Muc1 polyclonal antibody is successfully prepared. The antibody can specifically recognize the Muc1 protein in paralichthys ovatus mucosa tissue and positive mucous cells, and provides an important detection tool for studying the function mechanism of mucous cells in fish mucosal immunity.

This invention relates to the field of biotechnology, specifically to a monoclonal antibody against respiratory syncytial virus (RSV), its preparation method, and its applications. The RSV monoclonal antibody provided by this invention can recognize specific antigenic epitopes of the pre-F protein of RSV. Results from examples show that the monoclonal antibody has a strong affinity for the RSV F protein and exhibits high neutralizing efficacy against both RSV types A and B, thus preventing RSV infection. The drug for treating RSV provided by this invention contains a monoclonal antibody against RSV and provides good protection against RSV infection. The preparation method of the RSV monoclonal antibody provided by this invention is cost-effective and simple to operate.

The application provides a mycoplasma gallisepticum triple subunit vaccine and application thereof, and the vaccine comprises EF-TU protein with an amino acid sequence as shown in SEQ ID NO. 1, PdHD protein with an amino acid sequence as shown in SEQ ID NO. 2, MS1360 protein with an amino acid sequence as shown in SEQ ID NO. 3 and a pharmaceutically acceptable adjuvant. The application realizes antigen epitope complementation and immune synergistic enhancement by screening the optimal vaccine formula through two-by-two mixed combination and three-protein concentration gradient mixed system screening of EF-TU, PdHD and MS1360 three high immunogenic membrane proteins, and solves the problems of low protection rate and unstable immune effect of the existing vaccine.

The application belongs to the technical field of biological medicine, and particularly relates to an African swine fever virus p30 protein antigen epitope peptide, a monoclonal antibody and application. The African swine fever virus p30 protein antigen epitope peptide is located at 140-155 aa of the p30 protein, and the amino acid sequence is shown as SEQ ID NO:1. The nucleotide sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO:3; and the nucleotide sequence of the light chain variable region is shown as SEQ ID NO:4. The monoclonal antibody can specifically recognize the antigen epitope peptide. The specific recognition of the antigen epitope peptide provides a basis for establishing an efficient method for detecting the African swine fever virus, and also lays a foundation for studying the structure and function of the p30 protein.

The present application belongs to the technical field of immunotherapy, and particularly relates to an antigen epitope peptide of lymphocyte antigen 6 complex site K and application thereof. The present application aims to provide a new method for treating or clinically detecting tumors with high expression of LY6K. The technical scheme of the present application is an antigen epitope peptide of lymphocyte antigen 6 complex site K, and the amino acid sequence is shown in SEQ ID No. 7. The present application provides an LY6K antigen epitope peptide, and the antigen epitope peptide can be used to prepare a pMHC complex or directly load an antigen presenting cell to activate T cells. Therefore, the antigen epitope peptide can be applied to the treatment or diagnosis of tumors with high expression of LY6K antigen.

The application relates to a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof, relates to the technical field of biology, and aims to provide a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof.The amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown in a sequence table SEQ ID NO.1, and the amino acid sequence of a light chain variable region is shown in a sequence table SEQ ID NO.2.The application adopts Western blot and IFA methods to identify the reactivity of MAb, and identifies an antigen epitope recognized by MAb.The antigen epitope is conservative in type I cat coronavirus, which indicates that the monoclonal antibody can recognize various type I FCoV strains, has broad spectrum, and is not accidentally directed to a single strain.The antigen epitope has no cross reaction with type II, which indicates that the specificity is high, can be used for distinguishing type I and type II infections, and has diagnostic application value.

Anti-parasitic compounds and uses thereof. Compounds comprising a C-terminal peptide adjuvant conjugated to an N-terminal peptide antigen via a protease-cleavable linker, said peptide adjuvant comprising a peptide analog of C5a, wherein said peptide antigen comprises an antigenic epitope of a parasitic organism, such as T. gondii. Methods of therapeutic or prophylactic treatment of a parasitic infections.